Abeona therapeutics® reports first quarter 2025 financial results and corporate updates

- received approval by u.s. food and drug administration (fda) for zevaskyn™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric patients with recessive dystrophic epidermolysis bullosa (rdeb) - - u.s. launch of zevaskyn underway with activation of first qualified treatment center (qtc) - - entered into sales agreement for priority review voucher (prv) for $155 million - cleveland, may 15, 2025 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational progress. “zevaskyn's approval just a few weeks ago is a landmark achievement for recessive dystrophic epidermolysis bullosa patients and signifies abeona's transition to a commercial-stage cell and gene therapy company,” said vish seshadri, chief executive officer of abeona.
ABEO Ratings Summary
ABEO Quant Ranking